The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm?

IF 8.3 2区材料科学 Q1 MATERIALS SCIENCE, MULTIDISCIPLINARY

ACS Applied Materials & Interfaces Pub Date : 2024-09-18 DOI:10.1016/j.critrevonc.2024.104515

Jacopo Venturini , Giulia Massaro , Daniele Lavacchi , Daniele Rossini , Serena Pillozzi , Enrico Caliman , Elisa Pellegrini , Lorenzo Antonuzzo

{"title":"The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm?","authors":"Jacopo Venturini , Giulia Massaro , Daniele Lavacchi , Daniele Rossini , Serena Pillozzi , Enrico Caliman , Elisa Pellegrini , Lorenzo Antonuzzo","doi":"10.1016/j.critrevonc.2024.104515","DOIUrl":null,"url":null,"abstract":"<div><div>Colorectal cancer (CRC) represents a global health threat, standing as the second leading cause of cancer-related death worldwide. Targeted therapies brought new hope for the metastatic stage, which historically bore a very poor prognosis. Human epidermal growth receptor 2 (HER2) overexpression concerns about 5 % of the metastatic CRC (mCRC) patients, including both gene amplifications and point mutations. Albeit its controversial prognostic role, preclinical and clinical data indicate HER2 as a negative predictive biomarker of response to anti-EGFR therapies. Tissue and plasma-based NGS testing, could permit a precise identification of this resistance mechanism both at baseline and during treatment, thus guiding decision-making. Furthermore, promising results come from completed and ongoing randomized trials, testing HER2 as an actionable target. In this review, we discuss the available evidence on HER2 targeting in advanced CRC, analyzing its possible future role in the treatment algorithm.</div></div>","PeriodicalId":5,"journal":{"name":"ACS Applied Materials & Interfaces","volume":null,"pages":null},"PeriodicalIF":8.3000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1040842824002580/pdfft?md5=eab9df80d555f02399a513bf0b2e25d1&pid=1-s2.0-S1040842824002580-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Materials & Interfaces","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842824002580","RegionNum":2,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MATERIALS SCIENCE, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Colorectal cancer (CRC) represents a global health threat, standing as the second leading cause of cancer-related death worldwide. Targeted therapies brought new hope for the metastatic stage, which historically bore a very poor prognosis. Human epidermal growth receptor 2 (HER2) overexpression concerns about 5 % of the metastatic CRC (mCRC) patients, including both gene amplifications and point mutations. Albeit its controversial prognostic role, preclinical and clinical data indicate HER2 as a negative predictive biomarker of response to anti-EGFR therapies. Tissue and plasma-based NGS testing, could permit a precise identification of this resistance mechanism both at baseline and during treatment, thus guiding decision-making. Furthermore, promising results come from completed and ongoing randomized trials, testing HER2 as an actionable target. In this review, we discuss the available evidence on HER2 targeting in advanced CRC, analyzing its possible future role in the treatment algorithm.

查看原文本刊更多论文

结直肠癌中新出现的 HER2 标志：揭示未来治疗算法的关键？

结直肠癌（CRC）对全球健康构成威胁，是全球癌症相关死亡的第二大原因。靶向疗法为转移期癌症带来了新希望，因为转移期癌症的预后历来很差。约有 5% 的转移性 CRC（mCRC）患者存在人类表皮生长受体 2（HER2）过表达，包括基因扩增和点突变。尽管其预后作用存在争议，但临床前和临床数据表明，HER2 是抗 EGFR 疗法反应的阴性预测生物标志物。基于组织和血浆的 NGS 检测可以在基线和治疗过程中精确识别这种耐药机制，从而为决策提供指导。此外，已完成和正在进行的随机试验也取得了令人鼓舞的结果，这些试验将 HER2 作为一个可操作的靶点进行测试。在本综述中，我们将讨论晚期 CRC 中 HER2 靶向治疗的现有证据，分析其在治疗算法中未来可能发挥的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Materials & Interfaces 工程技术-材料科学：综合

CiteScore

16.00

自引率

6.30%

发文量

4978

审稿时长

1.8 months

期刊介绍： ACS Applied Materials & Interfaces is a leading interdisciplinary journal that brings together chemists, engineers, physicists, and biologists to explore the development and utilization of newly-discovered materials and interfacial processes for specific applications. Our journal has experienced remarkable growth since its establishment in 2009, both in terms of the number of articles published and the impact of the research showcased. We are proud to foster a truly global community, with the majority of published articles originating from outside the United States, reflecting the rapid growth of applied research worldwide.